ESPR · Insider Trading
Esperion Therapeutics, Inc.
Every open-market purchase and sale reported by ESPR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-13 | John B. Harlow Jr. | Chief Commercial Officer | D | −424,536 | — |
| 2026-07-13 | J Martin Carroll | Director | D | −177,523 | — |
| 2026-07-13 | Benjamin Looker | Chief Legal Officer | D | −667,524 | — |
| 2026-07-13 | Jay Shepard | Director | D | −164,472 | — |
| 2026-07-13 | Benjamin Halladay | Chief Financial Officer | D | −705,410 | — |
| 2026-07-13 | Robert E. Hoffman | Director | D | −85,153 | — |
| 2026-07-13 | Sheldon L. Koenig | President and CEO | D | −2,121,094 | — |
| 2026-07-13 | Seth H. Z. Fischer | Director | D | −141,023 | — |
| 2026-07-13 | John Craig Thompson | Director | D | −79,873 | — |
| 2026-06-18 | Sheldon L. Koenig | President and CEO | Sell | −53,588 | −$169.07K |
| 2026-06-18 | Benjamin Halladay | Chief Financial Officer | Sell | −10,773 | −$33.99K |
| 2026-06-18 | Benjamin Looker | Chief Legal Officer | Sell | −11,824 | −$37.30K |
| 2026-06-01 | J Martin Carroll | Director | A | +79,873 | — |
| 2026-06-01 | Robert E. Hoffman | Director | A | +79,873 | — |
| 2026-06-01 | John Craig Thompson | Director | A | +79,873 | — |
| 2026-06-01 | Seth H. Z. Fischer | Director | A | +79,873 | — |
| 2026-06-01 | Jay Shepard | Director | A | +79,873 | — |
| 2026-03-18 | Sheldon L. Koenig | President and CEO | Sell | −25,578 | −$69.55K |
| 2026-03-18 | Benjamin Halladay | Chief Financial Officer | Sell | −6,424 | −$17.38K |
| 2026-03-18 | Benjamin Looker | Chief Legal Officer | Sell | −5,708 | −$15.43K |
| 2026-03-16 | Benjamin Looker | Chief Legal Officer | A | +300,840 | — |
| 2026-03-16 | Sheldon L. Koenig | President and CEO | A | +723,760 | — |
| 2026-03-16 | Benjamin Halladay | Chief Financial Officer | A | +247,430 | — |
| 2026-01-21 | Benjamin Looker | General Counsel | Sell | −1,689 | −$4.87K |
| 2025-12-18 | Benjamin Halladay | Chief Financial Officer | Sell | −7,337 | −$26.90K |
| 2025-12-18 | Benjamin Looker | General Counsel | Sell | −6,517 | −$23.90K |
| 2025-12-18 | Sheldon L. Koenig | President and CEO | Sell | −48,244 | −$177.20K |
| 2025-12-08 | John B. Harlow Jr. | Chief Commercial Officer | A | +424,536 | — |
| 2025-10-20 | Benjamin Looker | General Counsel | Sell | −1,248 | −$3.28K |
| 2025-09-18 | Benjamin Looker | General Counsel | Sell | −6,267 | −$17.57K |
| 2025-09-18 | Sheldon L. Koenig | President and CEO | Sell | −28,427 | −$79.25K |
| 2025-09-18 | Benjamin Halladay | Chief Financial Officer | Sell | −7,046 | −$19.79K |
| 2025-07-18 | Benjamin Halladay | Chief Financial Officer | Sell | −11 | −$12 |
| 2025-07-18 | Benjamin Looker | General Counsel | Sell | −1,304 | −$1.47K |
| 2025-07-02 | John Craig Thompson | Director | A | +40,000 deriv. | — |
| 2025-06-18 | Benjamin Halladay | Chief Financial Officer | Sell | −7,229 | −$8.33K |
| 2025-06-18 | Benjamin Looker | General Counsel | Sell | −6,422 | −$7.40K |
| 2025-06-18 | Sheldon L. Koenig | President and CEO | Sell | −30,474 | −$33.80K |
| 2025-06-02 | Nicole Vitullo | Director | A | +88,000 deriv. | — |
| 2025-06-02 | Robert E. Hoffman | Director | A | +5,280 | — |
| 2025-06-02 | J Martin Carroll | Director | A | +33,000 | — |
| 2025-06-02 | Jay Shepard | Director | A | +33,000 | — |
| 2025-06-02 | Tracy M Woody | Director | A | +88,000 deriv. | — |
| 2025-06-02 | Stephen Rocamboli | Director | A | +33,000 | — |
| 2025-06-02 | Seth H. Z. Fischer | Director | A | +33,000 | — |
| 2025-04-21 | Benjamin Halladay | Chief Financial Officer | Sell | −8 | −$8 |
| 2025-04-21 | Eric Warren | Chief Commercial Officer | Sell | −108 | −$106 |
| 2025-04-02 | Robert E. Hoffman | Director | A | +40,000 deriv. | — |
| 2025-03-19 | Benjamin Halladay | Chief Financial Officer | Sell | −3,535 | −$5.24K |
| 2025-03-19 | Eric Warren | Chief Commercial Officer | Sell | −2,433 | −$3.62K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Eric Warren | Chief Commercial Officer | 370,218 | $1.18M |
| Stephen Rocamboli | Director | 69,261 | $220.25K |
| Nicole Vitullo | Director | 36,918 | $117.40K |
| Tracy M Woody | Director | 33,566 | $106.74K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ESPR quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.